A new year brings new developments in diabetes care, and tech improvements in insulin pumps and continuous glucose monitoring systems.
The New Year means we can expect new developments in diabetes care and treatment. And this year promises some exciting and innovative diabetes products, including new, more technologically advanced insulin pumps and improvements in continuous glucose monitoring systems.
Here is what is on the horizon for diabetes care in 2016:
Advances in insulin pumps in the coming year will include making the pumps thinner and easier to use, and having them function more like smartphones. Insulet is developing a next generation controller for their patch insulin pump, the Phoenix EDM, which will be thinner and have a touchscreen interface. A new version of the Medtronic Minimed Insulin Pump is also expected that will add predictive LGS capabilities as well as a new user interface and buttons.
Blood Glucose Monitors
Exciting changes are also being made to diabetes monitors. The Abbot Freestyle Libra, expected to be released this year, will employ a first-of-its-kind factory-calibrated flash system to allow users to scan a sensor and display a reading at any time.
Dexcom is also expected to release a new version of their monitor in 2016. It’s still not known all the new features the G6 version will have, but one expected improvement is that it will not require calibration.
Novo is on track to release a faster version of their Novolog for type 1 and 2 diabetes. The new version is expected to improve post-meal glucose levels by combining a short-acting insulin and two well-known excipients, a vitamin and an amino acid. Lilly also has a new basal insulin, Basaglar, which was just approved by the FDA and should be available before the end of the year.
Other New Diabetes Treatments
Combination drugs will continue to be the focus for the drug companies in 2016. Sanofi filed a new drug application last fall for its GLP-1 agonist Lyxumia (lixisenatide) and once that is approved, experts expect approval for combination drug Lixilan (Lyxumia+Lantus) to follow. Novo Nordisk also has a combination drug, Xultophy, a blend of GLP-1 agonist Victoza and their new basal insulin Tresiba, expected to hit the market later this year.
In addition to these new combo drugs, a new nasal glucagon is coming soon. Eli Lilly and Company acquired the rights to Locemia’s novel nasal glucagon that is reported to be easier to carry and use. Lilly is expected to file for approval for this device early this year.